[go: up one dir, main page]

DE60309927D1 - Gen 2.2 dendritische zell linien - Google Patents

Gen 2.2 dendritische zell linien

Info

Publication number
DE60309927D1
DE60309927D1 DE60309927T DE60309927T DE60309927D1 DE 60309927 D1 DE60309927 D1 DE 60309927D1 DE 60309927 T DE60309927 T DE 60309927T DE 60309927 T DE60309927 T DE 60309927T DE 60309927 D1 DE60309927 D1 DE 60309927D1
Authority
DE
Germany
Prior art keywords
hpdc
vitro
cell lines
line
dendritical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60309927T
Other languages
English (en)
Other versions
DE60309927T2 (de
Inventor
Joel Plumas
Laurence Chaperot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Etablissement Francais du Sang
Original Assignee
Etablissement Francais du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etablissement Francais du Sang filed Critical Etablissement Francais du Sang
Application granted granted Critical
Publication of DE60309927D1 publication Critical patent/DE60309927D1/de
Publication of DE60309927T2 publication Critical patent/DE60309927T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Secondary Cells (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60309927T 2002-12-16 2003-12-16 Gen 2.2 dendritische zelllinien Expired - Lifetime DE60309927T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0215927 2002-12-16
FR0215927A FR2848565B1 (fr) 2002-12-16 2002-12-16 Lignee de cellules dendritiques gen2.2
PCT/FR2003/003748 WO2004061089A1 (fr) 2002-12-16 2003-12-16 Lignee de cellules dendritiques gen2.2

Publications (2)

Publication Number Publication Date
DE60309927D1 true DE60309927D1 (de) 2007-01-04
DE60309927T2 DE60309927T2 (de) 2007-08-30

Family

ID=32338835

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60309927T Expired - Lifetime DE60309927T2 (de) 2002-12-16 2003-12-16 Gen 2.2 dendritische zelllinien

Country Status (8)

Country Link
US (1) US7341870B2 (de)
EP (1) EP1572989B1 (de)
AT (1) ATE346140T1 (de)
AU (1) AU2003300629B2 (de)
CA (1) CA2510596C (de)
DE (1) DE60309927T2 (de)
FR (1) FR2848565B1 (de)
WO (1) WO2004061089A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
WO2016082034A1 (en) * 2014-11-24 2016-06-02 Mickie Bhatia Non-monocytic dendritic cells, precursors thereof, and associated methods
WO2017214285A1 (en) 2016-06-07 2017-12-14 Eynav Klechevsky Detection of cd5 and methods and compositions for modulating cd5
WO2018134356A1 (en) 2017-01-20 2018-07-26 Etablissement Français Du Sang Method for predicting the clinical evolution of cancer patients
WO2018206577A1 (en) 2017-05-10 2018-11-15 Aarhus Universitet Interferon primed plasmacytoid dendritic cells
US20210277361A1 (en) * 2018-08-27 2021-09-09 Mican Technologies Inc. Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
EP4089170A4 (de) 2020-01-10 2023-07-19 Lg Chem, Ltd. Zusammensetzung, die antigen-präsentierende zellen umfasst, die mhc und tumorantigen gemeinsam exprimieren, und krebsbehandlung unter verwendung davon
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648219A (en) * 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
US7405076B2 (en) 2000-11-14 2008-07-29 Universite Libre De Bruxelles Generation and use of dendritic cells
AU2001217686A1 (en) 2000-11-14 2002-05-27 U.S. Army Medical Research Institute Of Infectious Diseases Method of establishing cultures of human dendritic cells and use thereof
US20030148316A1 (en) * 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
CA2388049A1 (en) * 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof

Also Published As

Publication number Publication date
DE60309927T2 (de) 2007-08-30
US7341870B2 (en) 2008-03-11
US20050272151A1 (en) 2005-12-08
EP1572989B1 (de) 2006-11-22
FR2848565A1 (fr) 2004-06-18
CA2510596C (en) 2011-09-20
ATE346140T1 (de) 2006-12-15
AU2003300629B2 (en) 2009-09-17
FR2848565B1 (fr) 2007-04-06
AU2003300629A1 (en) 2004-07-29
CA2510596A1 (en) 2004-07-22
WO2004061089A1 (fr) 2004-07-22
EP1572989A1 (de) 2005-09-14

Similar Documents

Publication Publication Date Title
SG151246A1 (en) Tissue system with undifferentiated stem cells derived from corneal limbus
WO2004050826A3 (en) Method of dynamically culturing embryonic stem cells
IL109381A (en) Method of isolating enriching and selectively propagating animal stem cells an animal cell and a vector for use in genetically modifying same
IL128221A (en) Cell adhesion inhibitors
JP2008503203A5 (de)
TW200500462A (en) Method for producing target substance by fermentation
BR0307349A (pt) Processos para fermentar uma composição de fitoesterol e para preparar androestadienodiona a partir da androestenodiona, fusarium solani fmi 33, e, composição
ATE346140T1 (de) Gen 2.2 dendritische zell linien
DK0971679T3 (da) Fremgangsmåde til opformering af hår
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
WO2007017915A3 (en) Use of common ϝ chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
DE60307615D1 (de) Zellkulturmedium
ATE479743T1 (de) Verfahren zur herstellung von zellkulturen aus biologischen präparaten für chemotherapeutische und andere assays
WO2004112835A3 (en) Suppression of transplant rejection
ATE335808T1 (de) Herstellung von zellsuspensionen
GB2450843A (en) Mutant HSV, materials and methods for generation of mutant HSV
AU2002361797A1 (en) Cell lines with latent immunodeficiency virus and methods of use thereof
WO2001049821A3 (fr) Lignees des lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
ATE213782T1 (de) Verfahren zur biotransformation von colchicinoid- verbindungen in die entsprechenden 3- glycosylderivate
WO2002036748A3 (en) Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
DE602005012962D1 (de) Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
MY157964A (en) Germ lineage derived feeder cells and methods thereof
IL165250A0 (en) Methods of donor specific crossmatching
GB2450059B (en) Culture system and method for propagation of human blastocyst-derived stem cells

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ETABLISSEMENT FRANCAIS DU SANG, LA PLAINE SANT, FR

8364 No opposition during term of opposition